BioMarin Pharmaceuticalvs.Vertex Pharmaceuticals
BMRN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 12× larger than BioMarin Pharmaceutical by market cap; Vertex Pharmaceuticals trades at the lower P/E (29.0 vs 144.9); year to date, Vertex Pharmaceuticals leads (+11.0% vs −7.6%).
Side by side
| BMRN | VRTX | |
|---|---|---|
| Market cap | $10.6B | $128B |
| Price | $54.80 | $510.08 |
| Today | −0.2% | +1.4% |
| Return YTD | −7.6% | +11.0% |
| Return 1Y | +0.4% | +19.5% |
| Since June 26, 2026 | −7.1% | +3.8% |
| P/E | 144.9 | 29.0 |
| P/S | 3.1 | 10.1 |
| P/B | 1.7 | 6.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More BMRN & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.